Spare us the unsupported conclusions shorty. First to market, market penetration, physician acceptance, distinguishing characteristics of the two tests, etc etc etc make drawing your conclusions that they will have lower profits just short seller BS speculation. We have just as much, and as little support, for a statement that Mama will not be accepted by the medical community because of (fill in the blank) and GHDX will dominate the field and increase profits.
I think the story has fundamentally changed now that there is an FDA approved direct competitor. I understand that approval is optional for this type of test, and GHDX seems to have decided to bypass it to get to market quickly. This would have been a good move if they had been able to use this position to get profitable or at least close. Now, they have squandered that advantage and face a new competitor with FDA approval. I've been a big bull on this stock but I'm out now.